In this context, different anti-LAG-3 antibodies are currently being used in phase I and phase II clinical trials as single drugs in metastatic cancer, solid tumor, and lymphoma (NCT03489369 and NCT03250832) or in association with other immune checkpoints inhibitors, including anti-TIM-3 antibody, in multiple myeloma patients (NCT04150965), with anti-PD-1 antibodies in treating patients with glioblastoma (NCT02658981), solid tumors (NCT01968109), advanced malignancies including lymphoma (NCT03005782), and SCCHN (NCT04080804) or other anti-PD-1 agents in solid tumor patients (NCT02676869). This evidence concerns the gene LAG3 and lymphoma.